US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-22 02:41:43 Source:worldViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Four people killed in a house explosion in southwestern Missouri
Next:This Week: Home sales, Fed meeting minutes and consumer sentiment index
You may also like
- How Robert F. Kennedy Jr. could make the first debate stage
- Birkin bags worth up to $100,000 become the number one target for burglars in LA
- FAFSA financial aid rollout leaves college dreams in limbo
- Lawmakers want the Chiefs and Royals to come to Kansas, but a stadium plan fizzled
- Socialite Jasmine Hartin enjoys beach snuggle with electrician hunk
- How AI is facing its 'Oppenheimer moment'
- FAFSA financial aid rollout leaves college dreams in limbo
- EU, UN reschedule launch of anti
- DR MARTIN SCURR: How losing your hearing may cause dementia